Arine utilizes AI algorithms to analyze clinical, behavioral, and social data, enabling proactive identification of medication-related issues before they escalate into costly health events. By optimizing medication management, Arine has demonstrated over 10% reduction in total care costs and a 40% decrease in hospitalizations across diverse patient populations.

CatenaBio’s CysTyr platform enables site‑specific conjugation of two or more drug payloads to a single antibody using a stable cystine‑tyrosine (C‑Y) bond. The resulting multi‑payload ADCs support flexible drug‑to‑antibody ratios and accommodate large or complex molecules, aiming to overcome resistance and improve therapeutic index in solid‑tumor indications. The technology integrates with existing antibody manufacturing processes for pharmaceutical and biotech developers.

Earli develops programmable genetic constructs that activate exclusively in cancer cells, prompting them to self-identify and undergo apoptosis. This technology addresses the challenge of early cancer detection and targeted therapy by enabling precise identification of malignant cells without affecting healthy tissue.

Enoda utilizes novel molecular tools and high-throughput screening to map underexplored cellular pathways for therapeutic enhancement. This approach allows them to rapidly engineer optimal cell phenotypes for specific disease indications. The company focuses on precisely engineering cell therapies to maximize their disease-fighting potential.

Examol provides computational drug discovery solutions leveraging advanced machine learning models for molecular design. The platform accelerates hit identification and lead optimization processes for pharmaceutical research. This technology enables researchers to rapidly screen and predict compound properties with high accuracy.

Fathom offers an AI-powered medical coding automation platform that can process millions of charts daily with over 90% accuracy, significantly reducing coding costs by up to 50%. The platform addresses staffing challenges and accelerates coding turnaround times, ensuring reliable and secure operations for healthcare providers.

Forum is a digital platform that connects individuals with facilitated peer support groups to help them navigate challenges such as grief, divorce, and career transitions. By offering virtual meetings led by experienced facilitators, Forum provides a safe and confidential space for members to share experiences and receive emotional support, making peer support accessible and convenient.

Freedom Biosciences is a biotechnology platform developing next-generation neuropsychiatric therapeutics based on ketamine pharmacology. The company focuses on creating novel antidepressants with improved efficacy and safety profiles for debilitating mental health disorders. Their pipeline includes clinical and preclinical programs targeting treatment-resistant depression and comorbid substance use disorders.

Journey Colab is developing synthetic Mescaline HCl as a therapeutic for patients with alcohol use disorder, integrating it with psychotherapy and community support to enhance treatment efficacy. The startup addresses the high relapse rates in addiction care by promoting durable remission through a scientifically validated and equitable care model.

Junction Health partners with Community Health Centers to enhance patient access to necessary medical services. The company achieves this by developing and managing integrated, on-site infusion centers within these facilities. This operational model supports the financial sustainability and growth of the partner health centers.

Juniper Genomics employs whole genome and transcriptome sequencing along with proprietary data analysis to enhance embryo selection in in vitro fertilization (IVF). By providing personalized insights based on comprehensive genetic data, the company increases the likelihood of successful embryo transfers, thereby improving IVF outcomes.

Keebler Health offers an AI-first risk adjustment platform that integrates diverse data sources, including FHIR and HIE, to enhance clinical decision support for medical billing teams. The platform improves accuracy in risk adjustment coding and streamlines workflows, enabling teams to uncover hidden complexities and expedite audits.

Macrotrials provides a hub‑and‑spoke clinical trial platform that centralizes site setup, regulatory, budgeting, and quality oversight while leveraging a network of community‑based investigators in ophthalmology, dermatology, and pulmonology. By embedding coordinators at each site, the company accelerates activation to weeks, delivers predictable enrollment across diverse U.S. populations, and ensures high‑quality data for Phase 2 and later pharmaceutical, biotech, and CRO studies.

Mae connects expectant mothers with community-based doulas and dedicated care coordinators to provide personalized support throughout pregnancy and postpartum. The platform integrates with health insurance plans to facilitate access to evidence-based maternal health resources and education. This integrated approach aims to improve maternal health outcomes, including reductions in preterm birth and C-section rates.

Persist AI accelerates drug formulation discovery by integrating an AI platform with high-throughput robotics in a cloud lab environment. This system allows scientists to design experiments remotely, which are then executed automatically to rapidly screen and predict formulations matching a target product profile. The company supports the entire process from initial discovery through to commercial cGMP manufacturing and analytical testing.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Rula is a digital platform that connects patients with licensed mental health providers through a streamlined matching process based on individual preferences and insurance coverage. By simplifying access to affordable therapy and psychiatry services, Rula addresses the challenge of finding suitable mental healthcare professionals quickly and efficiently.

Tidal Vision manufactures chitosan-based biomolecular solutions using its proprietary Chitofining™ Process and Zale Technology™ to address water treatment and agricultural challenges. Their products enhance efficiency and reduce environmental impact by providing high-concentration, zero-waste alternatives to traditional chemical solutions.

Vital Bio is developing the VitalOne, a point-of-care lab testing platform that utilizes microfluidics and computer vision to deliver lab-grade results from a small blood sample in minutes. This technology enables patients and healthcare providers to access real-time diagnostic information, facilitating timely interventions and improving health management.

Vivodyne provides a preclinical platform that utilizes lab-grown human organ tissue models for drug discovery and development. This platform enables high-throughput testing on thousands of human tissues to generate predictive human data before clinical trials. The resulting multimodal datasets power advanced AI models to refine new therapeutic targets and optimize drug candidates.

Waypoint is developing a cell therapy platform that utilizes spatial multi-omics and pooled screening to optimize the design and development of therapies for solid tumors. This approach enhances the accuracy and speed of therapy development by measuring both cell-autonomous and non-autonomous effects, addressing the limitations of traditional in vitro and in vivo methods.